AU2011248067B2 - Dosage unit formulations of autologous dermal fibroblasts - Google Patents

Dosage unit formulations of autologous dermal fibroblasts Download PDF

Info

Publication number
AU2011248067B2
AU2011248067B2 AU2011248067A AU2011248067A AU2011248067B2 AU 2011248067 B2 AU2011248067 B2 AU 2011248067B2 AU 2011248067 A AU2011248067 A AU 2011248067A AU 2011248067 A AU2011248067 A AU 2011248067A AU 2011248067 B2 AU2011248067 B2 AU 2011248067B2
Authority
AU
Australia
Prior art keywords
cells
treatment
fibroblasts
cell
dosage formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2011248067A
Other languages
English (en)
Other versions
AU2011248067A1 (en
Inventor
John Maslowski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Castle Creek Biosciences LLC
Original Assignee
Castle Creek Biosciences LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Castle Creek Biosciences LLC filed Critical Castle Creek Biosciences LLC
Publication of AU2011248067A1 publication Critical patent/AU2011248067A1/en
Application granted granted Critical
Publication of AU2011248067B2 publication Critical patent/AU2011248067B2/en
Assigned to CASTLE CREEK BIOSCIENCES, LLC reassignment CASTLE CREEK BIOSCIENCES, LLC Request for Assignment Assignors: FIBROCELL TECHNOLOGIES, INC.
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/33—Fibroblasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0656—Adult fibroblasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
AU2011248067A 2010-05-07 2011-05-05 Dosage unit formulations of autologous dermal fibroblasts Active AU2011248067B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12/776,163 US8529883B2 (en) 2010-05-07 2010-05-07 Dosage unit formulations of autologous dermal fibroblasts
US12/776,163 2010-05-07
PCT/US2011/035332 WO2011140323A1 (en) 2010-05-07 2011-05-05 Dosage unit formulations of autologous dermal fibroblasts

Publications (2)

Publication Number Publication Date
AU2011248067A1 AU2011248067A1 (en) 2012-12-20
AU2011248067B2 true AU2011248067B2 (en) 2015-03-12

Family

ID=44121161

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2011248067A Active AU2011248067B2 (en) 2010-05-07 2011-05-05 Dosage unit formulations of autologous dermal fibroblasts

Country Status (8)

Country Link
US (3) US8529883B2 (https=)
EP (1) EP2566489B1 (https=)
JP (1) JP6309268B2 (https=)
KR (1) KR102001254B1 (https=)
CN (2) CN102905711A (https=)
AU (1) AU2011248067B2 (https=)
CA (1) CA2800333C (https=)
WO (1) WO2011140323A1 (https=)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008027984A1 (en) 2006-08-29 2008-03-06 Isolagen Technologies, Inc. Methods for culturing minimally-passaged fibroblasts and uses thereof
US8512715B2 (en) * 2008-08-14 2013-08-20 The Cleveland Clinic Foundation Apparatus and method for treating a neuromuscular defect
WO2011075676A2 (en) 2009-12-18 2011-06-23 Knowlton Edward W A skin treatment and drug delivery device
US8529883B2 (en) * 2010-05-07 2013-09-10 Fibrocell Technologies, Inc. Dosage unit formulations of autologous dermal fibroblasts
US8765121B2 (en) * 2010-10-14 2014-07-01 Fibrocell Technologies, Inc. Treatment of vocal cords with autologous dermal fibroblast formulation
US11000310B2 (en) 2010-12-17 2021-05-11 Srgi Holdings, Llc Pixel array medical systems, devices and methods
US10736653B2 (en) 2013-12-06 2020-08-11 Srgi Holdings, Llc Pixel array medical systems, devices and methods
US10967162B2 (en) 2010-12-17 2021-04-06 Srgi Holdings, Llc Systems, devices and methods for fractional resection, fractional skin grafting, fractional scar reduction and fractional tattoo removal
US10702684B2 (en) 2010-12-17 2020-07-07 Srgi Holdings, Llc Systems, devices and methods for fractional resection, fractional skin grafting, fractional scar reduction and fractional tattoo removal
US11278309B2 (en) 2010-12-17 2022-03-22 Srgi Holdings, Llc Pixel array medical systems, devices and methods
US11103275B2 (en) 2010-12-17 2021-08-31 Srgi Holdings, Llc Pixel array medical systems, devices and methods
US11109887B2 (en) 2013-12-06 2021-09-07 Srgi Holdings, Llc Pixel array medical systems, devices and methods
CA2866563A1 (en) * 2012-03-07 2013-09-12 Fibrocell Technologies, Inc. Topical dermal formulations and methods of personalized treatment of skin
WO2013155109A1 (en) 2012-04-09 2013-10-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods for generation of pluripotent and multipotent cells
US20140072611A1 (en) * 2012-09-07 2014-03-13 Fibrocell Technologies, Inc. Methods and Compositions for Treating Post-Cardial Infarction Damage
ITMI20131053A1 (it) * 2013-06-25 2014-12-26 Maria Oliva Salviati Composizione che comprende ortica
BR112016007476A2 (pt) 2013-10-02 2017-09-12 Srgi Holdings Llc métodos e dispositivos médicos de conjunto de pixel
ES2827049T3 (es) 2013-10-02 2021-05-19 Srgi Holdings Llc Dispositivos médicos de conjunto de píxeles
US11229452B2 (en) 2013-12-06 2022-01-25 Srgi Holdings, Llc Pixel array medical systems, devices and methods
US11937846B2 (en) 2013-12-06 2024-03-26 Srgi Holdings Llc Pixel array medical systems, devices and methods
EP3579767B1 (en) 2014-10-02 2025-10-08 SRGI Holdings, LLC Pixel array medical systems and devices
EP3253308A4 (en) 2015-02-05 2018-10-24 SRGI Holdings LLC Pixel array medical systems, devices and methods
US11980389B2 (en) 2015-08-31 2024-05-14 Srgi Holdings Llc Handed spiral slotted scalpet array
US11751903B2 (en) 2015-08-31 2023-09-12 Srgi Holdings, Llc Pixel array medical systems, devices and methods
US11490952B2 (en) 2015-08-31 2022-11-08 Srgi Holdings, Llc Pixel array medical devices and methods
US12551509B2 (en) 2015-11-18 2026-02-17 Lucina Patent Holdco, Llc Acellular regenerative products and methods of their manufacture
WO2017100425A1 (en) * 2015-12-10 2017-06-15 Aesthetics Biomedical, Inc. Topical formulation for skin care
US11564706B2 (en) 2019-10-28 2023-01-31 Srgi Holdings, Llc Pixel array medical systems, devices and methods
WO2018217479A2 (en) 2017-05-11 2018-11-29 Srgi Holdings, Llc Systems, devices and methods for fractional resection, fractional skin grafting, fractional scar reduction and fractional tattoo removal
GB201818243D0 (en) * 2018-11-08 2018-12-26 Gammadelta Therapeutics Ltd Methods for isolating and expanding cells
US20220211767A1 (en) * 2019-04-27 2022-07-07 Figene, Llc Enhancement of fibroblast therapeutic activity by t cell modulation
US12544407B2 (en) 2019-04-28 2026-02-10 Fibrobiologics, Inc. Fibroblast cell therapy for treatment of osteoporosis
CN110075125A (zh) * 2019-05-10 2019-08-02 成都康景生物科技有限公司 一种用于治疗系统性硬化症伴随肢端硬化的脐带间充质干细胞注射液及其制备方法
AU2020387177B2 (en) 2019-11-22 2026-03-12 Cutiss Ag Methods and systems for producing skin grafts
AU2021245671A1 (en) * 2020-03-31 2022-10-20 Cell Exosome Therapeutics Inc. Cell preservation method
KR20220074132A (ko) 2020-11-27 2022-06-03 테고사이언스 (주) 건 재생 효과를 나타내는 피부 유래 섬유아세포 및 이의 용도
US20230293595A1 (en) * 2022-03-16 2023-09-21 Fibrobiologics, Inc. Therapeutic use of fibroblasts for use in wound healing
JP2023150483A (ja) * 2022-03-31 2023-10-16 ポーラ化成工業株式会社 コラーゲン代謝促進剤、及びコラーゲン代謝に関与する細胞群を特定する方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007138269A2 (en) * 2006-05-25 2007-12-06 Intercytex Limited Tissue repair
WO2008002064A1 (en) * 2006-06-26 2008-01-03 S-Biomedics Co., Ltd. Soft tissue filler composition for injection and preparation method thereof
WO2008027984A1 (en) * 2006-08-29 2008-03-06 Isolagen Technologies, Inc. Methods for culturing minimally-passaged fibroblasts and uses thereof
WO2008083223A1 (en) * 2006-12-28 2008-07-10 Isolagen Technologies, Inc. Methods for culturing dermal cells for treatment of skin injuries such as burns

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4524065A (en) 1983-08-04 1985-06-18 Bio-Specifics N.V. Method for the prevention and treatment of scars with enzymes
US4772557A (en) 1985-11-12 1988-09-20 Washington University DNA clone of human skin fibroblast collagenase enzyme
US5591444A (en) 1995-07-28 1997-01-07 Isolagen Technologies, Inc. Use of autologous dermal fibroblasts for the repair of skin and soft tissue defects
US20040229203A1 (en) * 1996-06-14 2004-11-18 Biostore New Zealand Ltd. Compositions and methods for the preservation of living tissues
AU6662698A (en) 1997-02-20 1998-09-09 Gregory S. Keller Augmentation and repair of dermal, subcutaneous, and vocal cord tissue defects
US7767452B2 (en) 1997-02-20 2010-08-03 Kleinsek Don A Tissue treatments with adipocyte cells
US6110459A (en) 1997-05-28 2000-08-29 Mickle; Donald A. G. Transplants for myocardial scars and methods and cellular preparations
US6150505A (en) * 1997-09-19 2000-11-21 Hadasit Medical Research Services & Development Ltd. Fibrin microbeads prepared from fibrinogen, thrombin and factor XIII
US7115417B1 (en) * 1998-05-01 2006-10-03 Chancellor Michael B Soft tissue and bone augmentation and bulking utilizing muscle-derived progenito compositions, and treatments thereof
US6432710B1 (en) 1998-05-22 2002-08-13 Isolagen Technologies, Inc. Compositions for regenerating tissue that has deteriorated, and methods for using such compositions
US7846465B1 (en) 1999-05-28 2010-12-07 Fibrocell Science, Inc. Method of using autologous fibroblasts to promote healing of wounds and fistulas
US6733530B1 (en) 1999-08-02 2004-05-11 Eric Sun-Yin Chan Material and method for engraftment of a composite biocompatible skin graft on the neodermis of artificial skin
US20080286242A2 (en) 1999-11-05 2008-11-20 Donald Kleinsek Augmentation and repair of spincter defects with cells including mesenchymal cells
US7799325B2 (en) 1999-11-05 2010-09-21 Kleinsek Donald A Removal of hypertrophic scars
US20040101959A1 (en) 2002-11-21 2004-05-27 Olga Marko Treatment of tissue with undifferentiated mesenchymal cells
US7186557B2 (en) 2003-06-13 2007-03-06 Isolagen Technologies, Inc. Methods of producing neurons
EP2399990B1 (en) 2003-06-27 2015-07-22 DePuy Synthes Products, Inc. Cells derived from post-partum umbilical cord for use in treatment of disease of the heart and circulatory system
EP1689284A4 (en) * 2003-11-10 2010-03-17 Symphony Medical Inc METHOD FOR REGULATING VENTRICULAR RHYTHM IN AURICULAR FIBRILLATION PATIENTS
EP1885280A1 (en) * 2005-05-26 2008-02-13 Intercytex Limited Tissue repair using allogenic dermal fibroblasts
US20090029340A1 (en) * 2006-01-04 2009-01-29 Do-Coop Technologies Ltd. Cryoprotective Compositions and Methods of Using Same
US20070264239A1 (en) * 2006-05-10 2007-11-15 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Isolation of pericytes
US20070298005A1 (en) * 2006-06-22 2007-12-27 Marie-Josee Thibault Injectable composition for treatment of skin defects or deformations
US20080015546A1 (en) * 2006-07-13 2008-01-17 Casas Jesus W Methods and formulations for optimal local delivery of cell therapy via minimally invasive procedures
WO2008081818A1 (ja) * 2006-12-28 2008-07-10 National University Corporation Nagoya University 皮膚組織改善材およびその製造方法
JP2008245583A (ja) * 2007-03-30 2008-10-16 Yamaguchi Univ 哺乳動物の神経細胞の精製培養方法とその保存方法
US7960098B2 (en) * 2007-07-12 2011-06-14 Warsaw Orthoperic, Inc. Methods and compositions for the preservation of cells and tissues
US20090191160A1 (en) 2007-08-10 2009-07-30 University Of Dayton Methods of producing pluripotent stem-like cells
JP2009148236A (ja) * 2007-12-20 2009-07-09 Glycoresearch Kk 線維芽細胞の細胞識別方法
US20090209456A1 (en) * 2008-02-19 2009-08-20 Iliana Sweis Compositions and methods for improving facial and body aesthetics
WO2009142717A2 (en) * 2008-05-19 2009-11-26 President And Fellows Of Harvard College Methods and products for dedifferentiation of cells
US8669048B2 (en) * 2008-06-24 2014-03-11 Parkinson's Institute Pluripotent cell lines and methods of use thereof
EP2297299A1 (en) * 2008-06-25 2011-03-23 INSERM - Institut National de la Santé et de la Recherche Médicale Methods for preparing human skin substitutes from human pluripotent stem cells
CA2752729A1 (en) * 2009-02-20 2010-08-26 Ventria Bioscience Cell culture media containing combinations of proteins
US8240314B2 (en) * 2009-04-06 2012-08-14 Eden Esthetics, A Professional Nursing Corporation Method for injecting fillers into the dermis
JP5816416B2 (ja) * 2010-04-23 2015-11-18 国立大学法人名古屋大学 細胞評価装置、インキュベータ、プログラム、および、培養方法
US8529883B2 (en) * 2010-05-07 2013-09-10 Fibrocell Technologies, Inc. Dosage unit formulations of autologous dermal fibroblasts

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007138269A2 (en) * 2006-05-25 2007-12-06 Intercytex Limited Tissue repair
WO2008002064A1 (en) * 2006-06-26 2008-01-03 S-Biomedics Co., Ltd. Soft tissue filler composition for injection and preparation method thereof
WO2008027984A1 (en) * 2006-08-29 2008-03-06 Isolagen Technologies, Inc. Methods for culturing minimally-passaged fibroblasts and uses thereof
WO2008083223A1 (en) * 2006-12-28 2008-07-10 Isolagen Technologies, Inc. Methods for culturing dermal cells for treatment of skin injuries such as burns

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WEISS R. et al, Autologous Cultured Fibroblast Injection for Facial Contour Deformities: A Prospective, Placebo-Controlled, Phase III Clinical Trial, DERMATOLOGIC SURGERY, 2007, Vol. 33, pg. 263-268 *

Also Published As

Publication number Publication date
AU2011248067A1 (en) 2012-12-20
JP6309268B2 (ja) 2018-04-11
KR20130060212A (ko) 2013-06-07
WO2011140323A1 (en) 2011-11-10
US11554142B2 (en) 2023-01-17
CA2800333A1 (en) 2011-11-10
KR102001254B1 (ko) 2019-07-17
JP2013524856A (ja) 2013-06-20
US20230270793A1 (en) 2023-08-31
EP2566489A1 (en) 2013-03-13
EP2566489B1 (en) 2019-04-24
CN107812014A (zh) 2018-03-20
US8529883B2 (en) 2013-09-10
CN107812014B (zh) 2021-11-16
US20110274665A1 (en) 2011-11-10
US20130295061A1 (en) 2013-11-07
CA2800333C (en) 2018-10-30
CN102905711A (zh) 2013-01-30

Similar Documents

Publication Publication Date Title
US20230270793A1 (en) Dosage Unit Formulations Of Autologous Dermal Fibroblasts
US10881695B2 (en) Treatment of vocal cords with autologous dermal fibroblast formulation
JP7386162B2 (ja) 線維芽細胞の再生活性の増強
JP2023513394A (ja) 細胞外小胞及びその皮膚製品における使用
CN102625689A (zh) 用于恢复面部或身体所选区域中年龄相关组织损失的方法和组合物
CN108057116A (zh) 干细胞组合物在皮肤损伤治疗药物中的应用
Yang et al. Platelet poor plasma gel combined with amnion improves the therapeutic effects of human umbilical cord‑derived mesenchymal stem cells on wound healing in rats
CN109136180A (zh) 人体脐带血间充质干细胞提取物及其制备方法和应用
CN102233144A (zh) 一种利用组织工程技术进行皮下组织再生的方法
CN108066750A (zh) 干细胞及其分泌物用于治疗皮肤烧烫伤的新用途
KR101083047B1 (ko) 간엽줄기세포의 배양방법 및 간엽줄기세포를 포함하는 피부결함의 치료용 조성물
CN108066824A (zh) 一种制备表皮缺损治疗药物的新方法
CN100581502C (zh) 一种注射用人体软组织填充剂及其制备方法
RU2455357C1 (ru) Клеточный продукт для аутологичных и аллогенных трансплантаций, полученный из плаценты человека, и способ его получения
HK1180968A (en) Dosage unit formulations of autologous dermal fibroblasts
CN108057131A (zh) 一种含有干细胞的新型试剂盒
Martins et al. Adipose tissue mature stem cells in skin healing: a controlled randomized study
Manturova et al. Treatment of Skin Wounds in Old Animals Using Mesenzymal Progenitor Cells and Polymer Gel Compositions
Şenel et al. Toxicological Analysis of a New Fibrin-Derived Dermal Scaffold (Dermoturk); Acellular and Combined with Stem Cells Forms
Dermo-epidermal PEDIATRIC/CRANIOFACIAL

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: CASTLE CREEK BIOSCIENCES, LLC

Free format text: FORMER OWNER(S): FIBROCELL TECHNOLOGIES, INC.